Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Direct Anti HCV Drugs in the Treatment of COVID-19
NCT04535869Phase 3Unknown
- Sponsor
- Mansoura University
- Start
- Dec 2020
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of sofosbuvir and daclatasvir in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Mansoura University. Primary endpoint: Rate of virological cure by Rt-PCR for COVID-19 at 2 weeks. Status: unknown.
02
Drugs
sofosbuvirdaclatasvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04535869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04535869.